Edgewise Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 38.9 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 4.22B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tr...